Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
MetadataShow full item record
<h4>Background</h4>Soft tissue sarcomas are a group of neoplasms with differentiation towards mesenchymal tissue, many of which are aggressive and chemotherapy resistant. Histology and immunoprofiles often overlap with neoplasms of other lineages, and establishing an accurate histopathological diagnosis is crucial for correct management, and therapeutic stratification. The endosialin cell surface glycoprotein is predominantly expressed by stromal fibroblasts and pericytes in epithelial neoplasms; however, tumour cell expression has been reported in small series of sarcomas.<h4>Methods</h4>We assessed endosialin expression by immunohistochemistry in a large set of 514 human soft tissue sarcomas.<h4>Results</h4>Tumour cell endosialin expression was seen in 89% of undifferentiated pleomorphic sarcomas (104/117), 77% adult fibrosarcomas/spindle cell sarcomas (20/26), 62% synovial sarcomas (37/60), 51% leiomyosarcomas (94/185) and 31% rhabdomyosarcomas (39/126).<h4>Conclusions</h4>Endosialin immunohistochemistry has potential to distinguish undifferentiated and poorly differentiated sarcomas from other poorly differentiated, non-mesenchymal neoplasms. A Phase II trial randomising patients with advanced sarcomas to receive chemotherapy with/without an endosialin therapeutic antibody has recently completed enrolment. Endosialin expression could be used to select patients for such clinical trials. Based on our results, patients with undifferentiated pleomorphic sarcoma may be particularly suitable for such a therapeutic approach.
Version of record
Molecular Cell Biology
Sarcoma Clinical Trials (R Jones)
Sarcoma Molecular Pathology
License start date
British journal of cancer, 2016, 115 (4), pp. 473 - 479